Literature DB >> 21744032

Measuring health-related quality-of-life for Alzheimer's disease using the general public.

Feng Xie1, Mark Oremus, Kathryn Gaebel.   

Abstract

PURPOSE: Little research exists to indicate whether the general public can provide proxy health-related quality-of-life (HRQoL) estimates for persons with Alzheimer's disease (AD). We investigated (1) whether the general public can differentiate between mild, moderate, and severe AD and (2) whether the general public's proxy HRQoL estimates are correlated with current health status.
METHODS: We conducted computer-assisted personal interviews. The computer randomly assigned each participant to read a vignette describing mild, moderate, or severe AD. Participants answered the EQ-5D-5L and Quality-of-life-Alzheimer's Disease (QoL-AD), while imagining living in the health state described in their assigned vignette. Participants also answered the EQ-5D-5L based on their health state at the time of the interview.
RESULTS: We interviewed 100 participants. EQ-5D-5L utilities were 0.7413 (mild), 0.6159 (moderate), and 0.4456 (severe) (P < 0.001). Mean QoL-AD scores were 32.5 (mild), 24.0 (moderate), and 21.8 (severe) (P < 0.0001 for severe vs. mild, moderate vs. mild; P > 0.05 for severe vs. moderate). Participants' EQ-5D-5L utility scores were weakly correlated (r ≤ 0.28) across both administrations of the instrument.
CONCLUSIONS: The general public can differentiate between the three stages of AD, and their HRQoL estimates for AD are weakly correlated with their current health status.

Entities:  

Mesh:

Year:  2011        PMID: 21744032     DOI: 10.1007/s11136-011-9966-8

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  31 in total

1.  Generic and disease-specific measures of quality of life in patients with mild Alzheimer's disease.

Authors:  Suvosree Bhattacharya; Asmus Vogel; Marie-Louise H Hansen; Frans B Waldorff; Gunhild Waldemar
Journal:  Dement Geriatr Cogn Disord       Date:  2010-10-02       Impact factor: 2.959

Review 2.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

3.  Utility-based Quality of Life measures in Alzheimer's disease.

Authors:  Gary Naglie; George Tomlinson; Catherine Tansey; Jane Irvine; Paul Ritvo; Sandra E Black; Morris Freedman; Michel Silberfeld; Murray Krahn
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

4.  Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients.

Authors:  A Simon Pickard; Maria C De Leon; Thomas Kohlmann; David Cella; Sarah Rosenbloom
Journal:  Med Care       Date:  2007-03       Impact factor: 2.983

5.  Caregivers' estimation of patients' quality of life (QoL) in Alzheimer's disease (AD): an approach using the ADRQL.

Authors:  Beatriz León-Salas; Javier Olazarán; Ruben Muñiz; Ma Teresa González-Salvador; Pablo Martínez-Martín
Journal:  Arch Gerontol Geriatr       Date:  2010-06-22       Impact factor: 3.250

6.  Caregivers' assessments of preference-based quality of life in Alzheimer's disease.

Authors:  Jason H Karlawish; Art Zbrozek; Bruce Kinosian; Annemarie Gregory; Allison Ferguson; Dominique V Low; Henry A Glick
Journal:  Alzheimers Dement       Date:  2008-04-24       Impact factor: 21.566

7.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

8.  Preference-based quality of life in patients with Alzheimer's disease.

Authors:  Jason H Karlawish; Art Zbrozek; Bruce Kinosian; Annemarie Gregory; Allison Ferguson; Henry A Glick
Journal:  Alzheimers Dement       Date:  2008-05-02       Impact factor: 21.566

9.  The Public's ability to recognize Alzheimer disease and their beliefs about its causes.

Authors:  Sergio Luís Blay; Erica de Toledo Piza Peluso
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jan-Mar       Impact factor: 2.703

10.  Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada.

Authors:  Mark Oremus; Jean-Eric Tarride; Natasha Clayton; Parminder Raina
Journal:  BMC Health Serv Res       Date:  2009-12-29       Impact factor: 2.655

View more
  3 in total

Review 1.  Identifying the components of clinical vignettes describing Alzheimer's disease or other dementias: a scoping review.

Authors:  Harkanwal Randhawa; Aalim Jiwa; Mark Oremus
Journal:  BMC Med Inform Decis Mak       Date:  2015-07-15       Impact factor: 2.796

2.  Development of Clinical Vignettes to Describe Alzheimer's Disease Health States: A Qualitative Study.

Authors:  Mark Oremus; Feng Xie; Kathryn Gaebel
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

3.  Can the general public use vignettes to discriminate between Alzheimer's disease health states?

Authors:  Mark Oremus; Feng Xie; Eleanor Pullenayegum; Kathryn Gaebel
Journal:  BMC Geriatr       Date:  2016-02-03       Impact factor: 3.921

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.